Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Tcelna: Ph IIb Abili-T data

February 1, 2017 10:16 PM UTC

Last October, Opexa reported top-line data from the double-blind, North American Phase IIb Abili-T trial in 183 patients with SPMS showing that subcutaneous Tcelna missed the primary endpoint of reduc...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Opexa Therapeutics Inc.

BCIQ Target Profiles

T cell receptor (TCR)